Across TCGA pan-cancer cohorts, NEK3 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated NEK3 data layer compared with 26 for mass-spec protein and 6 for mass-spec protein.
The strongest signal is observed in colon adenocarcinoma (COAD), where higher NEK3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated NEK3 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.
COAD and UCEC are the cancer types where NEK3 Mutation most reproducibly stratifies survival.